Stryker Corporation $SYK Shares Bought by Trivium Point Advisory LLC

Trivium Point Advisory LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 404.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,587 shares of the medical technology company’s stock after purchasing an additional 2,876 shares during the period. Trivium Point Advisory LLC’s holdings in Stryker were worth $1,326,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Rafferty Asset Management LLC grew its position in Stryker by 5.0% in the third quarter. Rafferty Asset Management LLC now owns 38,185 shares of the medical technology company’s stock worth $14,116,000 after buying an additional 1,826 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Stryker by 4.8% in the 3rd quarter. American Century Companies Inc. now owns 919,851 shares of the medical technology company’s stock worth $340,041,000 after acquiring an additional 42,188 shares during the last quarter. Harvest Portfolios Group Inc. grew its holdings in shares of Stryker by 2.7% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 148,868 shares of the medical technology company’s stock worth $55,032,000 after acquiring an additional 3,883 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Stryker during the third quarter worth $6,041,000. Finally, Ibex Wealth Advisors acquired a new position in shares of Stryker in the 3rd quarter valued at $510,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have issued reports on SYK. Needham & Company LLC boosted their price objective on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a report on Friday, January 30th. UBS Group lifted their target price on shares of Stryker from $386.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday. William Blair started coverage on shares of Stryker in a research report on Friday, February 20th. They issued an “outperform” rating for the company. Sanford C. Bernstein lifted their price objective on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Finally, Barclays reissued an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. Thirteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $426.47.

Stryker Stock Up 0.3%

Stryker stock opened at $387.34 on Friday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market cap of $148.23 billion, a PE ratio of 46.11, a P/E/G ratio of 2.26 and a beta of 0.87. The firm’s 50 day moving average price is $363.17 and its two-hundred day moving average price is $369.16.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the previous year, the company posted $4.01 EPS. Stryker’s revenue was up 11.4% on a year-over-year basis. On average, research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.